Want to see GB:GENF full AI Analyst Report?
Genflow Biosciences Plc (GENF) AI Stock Analysis
Genflow Biosciences Plc
(LSE:GENF)
The score is driven primarily by severe financial weakness, including persistent losses and substantial cash burn. Weak technical momentum and a negative P/E ratio further reduce the score, while the absence of debt provides only a limited positive offset.
Genflow Biosciences Plc (GENF) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 10.85M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.33M
- Price to Earnings (P/E)
- -8.3
- Beta (1Y)
- -0.19
- Revenue Growth
- ―
- EPS Growth
- 56.00%
- Country
- UK
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Genflow Biosciences Plc Business Overview & Revenue Model
Company Description
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company t...
Genflow Biosciences Plc Financial Statement Overview
Summary
Persistent operating losses, a 148% net loss margin, negative £1.23 million operating and free cash flow, and declining revenue indicate severe financial weakness. No debt and positive current equity provide limited offset.
Income Statement
15Very NegativeBalance Sheet
45NeutralCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 585.61K | 0 | 0 | 169.85K | 0 | 0 |
| Gross Profit | 585.61K | -1,093 | -1,204 | -1,034 | -130 | 0 |
| EBITDA | -1.10M | -2.00M | -1.59M | -1.80M | -1.33M | -988.10K |
| Net Income | -1.10M | -1.42M | -1.59M | -1.63M | -1.34M | -988.29K |
Balance Sheet | ||||||
| Total Assets | 748.99K | 452.39K | 385.91K | 1.07M | 2.62M | 276.55K |
| Cash, Cash Equivalents and Short-Term Investments | 632.55K | 111.79K | 278.68K | 683.97K | 2.36M | 224.00K |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 559.14K | 1.00M | 788.92K | 345.74K | 250.99K | 221.43K |
| Stockholders Equity | 189.85K | -550.78K | -403.01K | 725.91K | 2.37M | 55.12K |
Cash Flow | ||||||
| Free Cash Flow | -1.23M | -1.44M | -1.08M | -1.66M | -1.37M | -747.38K |
| Operating Cash Flow | -1.23M | -1.44M | -1.08M | -1.66M | -1.37M | -747.38K |
| Investing Cash Flow | -652 | 0 | 0 | -2,439 | -2,480 | 198.50K |
| Financing Cash Flow | 1.59M | 1.31M | 656.63K | 0 | 3.50M | 783.71K |
Genflow Biosciences Plc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GENF, the sentiment is Negative. The current price of 1.94 is above the 20-day moving average (MA) of 1.80, below the 50-day MA of 1.96, and below the 200-day MA of 2.03, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 46.80 is Neutral, neither overbought nor oversold. The STOCH value of 61.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:GENF.
Genflow Biosciences Plc Peers Comparison
Overall Rating
GB:4BB52Neutral
GB:FAB49Neutral
GB:APTA43Neutral
GB:PYC41.5Neutral- GB:GENF40Underperform
GB:OBD40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:4BB | 52Neutral | GBP 82.07M | -4.57 | -316.73% | ― | -56.10% | -16.77% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:FAB | 49Neutral | GBP 7.51M | -6.06 | -97.87% | ― | 7.38% | 44.13% |
| GB:APTA | 43Neutral | GBP 10.23M | -9.83 | -46.61% | ― | 28.35% | 57.14% |
| GB:PYC | 42Neutral | GBP 1.93M | -2.13 | -152.03% | ― | 20.05% | -11.11% |
| GB:GENF | 40Underperform | GBP 10.85M | -8.29 | 609.63% | ― | ― | 56.00% |
| GB:OBD | 40Underperform | GBP 14.45M | -0.27 | -451.74% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:GENF | Genflow Biosciences Plc | 1.82 | -0.25 | -12.05% | |
| GB:OBD | Oxford BioDynamics | 0.11 | -0.21 | -66.56% | |
| GB:PYC | Physiomics plc | 0.42 | 0.01 | 2.41% | |
| GB:FAB | Fusion Antibodies Plc | 6.00 | -6.75 | -52.94% | |
| GB:4BB | 4basebio UK Societas | 530.00 | -255.00 | -32.48% | |
| GB:APTA | Aptamer Group Plc | 0.29 | -0.52 | -64.02% |
Genflow Biosciences Plc Corporate Events
Genflow strengthens SIRT6 patent in Japan and broadens animal health pipeline
PositiveGenflow Biosciences has secured a decision to grant from the Japan Patent Office for a patent covering SIRT6 variants used to prevent and treat age-related diseases, reinforcing protection for the core gene therapy platform in one of the world’...
Genflow’s SIRT6c Gene Therapy Shows Promising Interim Results in Ageing Dog Trial
PositiveGenflow Biosciences reported interim results from its SLAB-VET-001 canine trial, a four-arm blinded study in 24 aged Beagles testing its centenarian-derived SIRT6c gene therapy delivered via plasmid DNA or AAV8 versus saline. The therapy was generall...
Genflow Biosciences boosts capital with warrant exercise and new share issuance
PositiveGenflow Biosciences Plc has strengthened its capital base through the exercise of warrants resulting in the issue of 28,124,999 new ordinary shares, generating gross proceeds of £309,375 for the company. The new shares, issued at an adjusted exe...
Genflow Biosciences Hits Canine Longevity Milestone and Expands Human Aging Pipeline
PositiveGenflow Biosciences reported half-year results marked by the successful completion of its SLAB clinical trial in aged Beagle dogs, confirming safety and tolerability of its GF-1004 SIRT6-based therapy and generating functional healthspan data. This m...
Genflow hits key ageing marker in dog gene‑therapy trial, eyes animal health deals
PositiveGenflow Biosciences has completed its SLAB clinical trial in aged beagles, testing a proprietary SIRT6 centenarian gene therapy delivered via naked DNA and AAV8, and achieved the primary endpoint of reducing biological age as measured by the GRIM met...
Genflow Biosciences hires ON365 to bolster investor outreach as SIRT6 gene therapy advances
PositiveGenflow Biosciences Plc, an emerging player in longevity research developing SIRT6-based gene therapies for age-related conditions, is advancing its lead candidate GF-1002 through preclinical and early clinical programmes. The company aims to address...
Genflow Advances SIRT6 Patent Portfolio to Bolster Longevity Gene Therapy Strategy
PositiveGenflow Biosciences, a UK-based biotechnology firm specializing in gene therapies for age-related diseases and longevity, is advancing its lead SIRT6-based candidate GF-1002 through preclinical and clinical programs. The company aims to address signi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 14, 2026